Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Mirati Ther stock

Learn how to easily invest in Mirati Ther stock.

Mirati Ther is a biotechnology business based in the US. Mirati Ther shares (MRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Mirati Ther employs 413 staff and has a trailing 12-month revenue of around $78.2 million.

How to buy shares in Mirati Ther

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Mirati Ther stock price (NASDAQ: MRTX)

Use our graph to track the performance of MRTX stocks over time.

Mirati Ther shares at a glance

Information last updated 2022-09-26.
Latest market close$67.56
52-week range$32.96 - $195.99
50-day moving average $75.96
200-day moving average $85.58
Wall St. target price$120.21
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-11.96

Buy Mirati Ther shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Mirati Ther stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mirati Ther price performance over time

Historical closes compared with the close of $67.56 from 2022-09-27

1 week (2022-09-22) -3.40%
1 month (2022-08-29) -10.11%
3 months (2022-06-29) 0.48%
6 months (2022-03-29) -20.29%
1 year (2021-09-29) -61.23%
2 years (2020-09-29) -59.31%
3 years (2019-09-27) 84.42
5 years (2017-09-28) 495.24%

Mirati Ther financials

Revenue TTM $78.2 million
Gross profit TTM $72.1 million
Return on assets TTM -30.26%
Return on equity TTM -57.52%
Profit margin 0%
Book value $20.00
Market capitalisation $3.8 billion

TTM: trailing 12 months

Mirati Ther share dividends

We're not expecting Mirati Ther to pay a dividend over the next 12 months.

Have Mirati Ther's shares ever split?

Mirati Ther's shares were split on a 1:50 basis on 2 July 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mirati Ther shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Mirati Ther shares which in turn could have impacted Mirati Ther's share price.

Mirati Ther share price volatility

Over the last 12 months, Mirati Ther's shares have ranged in value from as little as $32.96 up to $195.99. A popular way to gauge a stock's volatility is its "beta".

MRTX.US volatility(beta: 0.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mirati Ther's is 0.9085. This would suggest that Mirati Ther's shares are less volatile than average (for this exchange).

Mirati Ther overview

Mirati Therapeutics, Inc. , a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Frequently asked questions

What percentage of Mirati Ther is owned by insiders or institutions?
Currently 1.649% of Mirati Ther shares are held by insiders and 114.983% by institutions.
How many people work for Mirati Ther?
Latest data suggests 413 work at Mirati Ther.
When does the fiscal year end for Mirati Ther?
Mirati Ther's fiscal year ends in December.
Where is Mirati Ther based?
Mirati Ther's address is: 3545 Cray Court, San Diego, CA, United States, 92121
What is Mirati Ther's ISIN number?
Mirati Ther's international securities identification number is: US60468T1051
What is Mirati Ther's CUSIP number?
Mirati Ther's Committee on Uniform Securities Identification Procedures number is: 60468T105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site